 | • レポートコード：D0GIR-00891 • 出版社/出版日：GlobalInfoResearch / 2020年9月18日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、薬物再プロファイリングの世界市場を広く調査・分析し、今後の市場展望をまとめております。薬物再プロファイリングの種類別市場規模（経口、静脈内）、用途別市場規模（中枢神経障害、心臓血管障害、腫瘍学、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Novartis AG、Teva Pharmaceuticals、Johnson & Johnson、Abbott Healthcare、Mylan Inc.、Pfizer、Sandoz、Hoffmann-La Roche ・地域別グローバル市場分析 2015年-2020年 ・薬物再プロファイリングの北米市場（アメリカ、カナダ、メキシコ） ・薬物再プロファイリングのヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・薬物再プロファイリングのアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・薬物再プロファイリングの南米市場（ブラジル、アルゼンチン） ・薬物再プロファイリングの中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：経口、静脈内 ・用途別分析：中枢神経障害、心臓血管障害、腫瘍学、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The Drug Reprofiling market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global Drug Reprofiling sales will be xx in 2020 from Drug Reprofiling million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Drug Reprofiling market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the Drug Reprofiling industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Drug Reprofiling and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
Drug Reprofiling market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Drug Reprofiling market has been segmented into:
Orally
Intravenously
By Application, Drug Reprofiling has been segmented into:
Central Nervous Disorders
Cardiovascular Disorders
Oncology
others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Drug Reprofiling market presented in the report. This section sheds light on the sales growth of different regional and country-level Drug Reprofiling markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Drug Reprofiling market.
The report offers in-depth assessment of the growth and other aspects of the Drug Reprofiling market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Drug Reprofiling Market Share Analysis
Drug Reprofiling competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Drug Reprofiling sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Drug Reprofiling sales, revenue and market share for each player covered in this report.
The major players covered in Drug Reprofiling are:
Novartis AG
Teva Pharmaceuticals
Johnson & Johnson
Abbott Healthcare
Mylan Inc.
Pfizer
Sandoz
Hoffmann-La Roche
Among other players domestic and global, Drug Reprofiling market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
1 Drug Reprofiling Market Overview
1.1 Product Overview and Scope of Drug Reprofiling
1.2 Classification of Drug Reprofiling by Type
1.2.1 Global Drug Reprofiling Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Drug Reprofiling Revenue Market Share by Type in 2019
1.2.3 Orally
1.2.4 Intravenously
1.3 Global Drug Reprofiling Market by Application
1.3.1 Overview: Global Drug Reprofiling Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Central Nervous Disorders
1.3.3 Cardiovascular Disorders
1.3.4 Oncology
1.3.5 others
1.4 Global Drug Reprofiling Market by Regions
1.4.1 Global Drug Reprofiling Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Drug Reprofiling (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Drug Reprofiling Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Drug Reprofiling Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Drug Reprofiling Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Drug Reprofiling Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Drug Reprofiling Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Drug Reprofiling Industry Impact
1.5.1 COVID-19 Potential Implications for the Drug Reprofiling
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Drug Reprofiling
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Novartis AG
2.1.1 Novartis AG Details
2.1.2 Novartis AG Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Novartis AG SWOT Analysis
2.1.4 Novartis AG Product and Services
2.1.5 Novartis AG Drug Reprofiling Revenue, Gross Margin and Market Share (2018-2019)
2.2 Teva Pharmaceuticals
2.2.1 Teva Pharmaceuticals Details
2.2.2 Teva Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Teva Pharmaceuticals SWOT Analysis
2.2.4 Teva Pharmaceuticals Product and Services
2.2.5 Teva Pharmaceuticals Drug Reprofiling Revenue, Gross Margin and Market Share (2018-2019)
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Johnson & Johnson SWOT Analysis
2.3.4 Johnson & Johnson Product and Services
2.3.5 Johnson & Johnson Drug Reprofiling Revenue, Gross Margin and Market Share (2018-2019)
2.4 Abbott Healthcare
2.4.1 Abbott Healthcare Details
2.4.2 Abbott Healthcare Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Abbott Healthcare SWOT Analysis
2.4.4 Abbott Healthcare Product and Services
2.4.5 Abbott Healthcare Drug Reprofiling Revenue, Gross Margin and Market Share (2018-2019)
2.5 Mylan Inc.
2.5.1 Mylan Inc. Details
2.5.2 Mylan Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Mylan Inc. SWOT Analysis
2.5.4 Mylan Inc. Product and Services
2.5.5 Mylan Inc. Drug Reprofiling Revenue, Gross Margin and Market Share (2018-2019)
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Pfizer SWOT Analysis
2.6.4 Pfizer Product and Services
2.6.5 Pfizer Drug Reprofiling Revenue, Gross Margin and Market Share (2018-2019)
2.7 Sandoz
2.7.1 Sandoz Details
2.7.2 Sandoz Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Sandoz SWOT Analysis
2.7.4 Sandoz Product and Services
2.7.5 Sandoz Drug Reprofiling Revenue, Gross Margin and Market Share (2018-2019)
2.8 Hoffmann-La Roche
2.8.1 Hoffmann-La Roche Details
2.8.2 Hoffmann-La Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Hoffmann-La Roche SWOT Analysis
2.8.4 Hoffmann-La Roche Product and Services
2.8.5 Hoffmann-La Roche Drug Reprofiling Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Drug Reprofiling Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Drug Reprofiling Players Market Share
3.2.2 Top 10 Drug Reprofiling Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Drug Reprofiling Revenue and Market Share by Regions
4.2 North America Drug Reprofiling Revenue and Growth Rate (2015-2020)
4.3 Europe Drug Reprofiling Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Drug Reprofiling Revenue and Growth Rate (2015-2020)
4.5 South America Drug Reprofiling Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Drug Reprofiling Revenue and Growth Rate (2015-2020)
5 North America Drug Reprofiling Revenue by Countries
5.1 North America Drug Reprofiling Revenue by Countries (2015-2020)
5.2 USA Drug Reprofiling Revenue and Growth Rate (2015-2020)
5.3 Canada Drug Reprofiling Revenue and Growth Rate (2015-2020)
5.4 Mexico Drug Reprofiling Revenue and Growth Rate (2015-2020)
6 Europe Drug Reprofiling Revenue by Countries
6.1 Europe Drug Reprofiling Revenue by Countries (2015-2020)
6.2 Germany Drug Reprofiling Revenue and Growth Rate (2015-2020)
6.3 UK Drug Reprofiling Revenue and Growth Rate (2015-2020)
6.4 France Drug Reprofiling Revenue and Growth Rate (2015-2020)
6.5 Russia Drug Reprofiling Revenue and Growth Rate (2015-2020)
6.6 Italy Drug Reprofiling Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Drug Reprofiling Revenue by Countries
7.1 Asia-Pacific Drug Reprofiling Revenue by Countries (2015-2020)
7.2 China Drug Reprofiling Revenue and Growth Rate (2015-2020)
7.3 Japan Drug Reprofiling Revenue and Growth Rate (2015-2020)
7.4 Korea Drug Reprofiling Revenue and Growth Rate (2015-2020)
7.5 India Drug Reprofiling Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Drug Reprofiling Revenue and Growth Rate (2015-2020)
8 South America Drug Reprofiling Revenue by Countries
8.1 South America Drug Reprofiling Revenue by Countries (2015-2020)
8.2 Brazil Drug Reprofiling Revenue and Growth Rate (2015-2020)
8.3 Argentina Drug Reprofiling Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Drug Reprofiling by Countries
9.1 Middle East & Africa Drug Reprofiling Revenue by Countries (2015-2020)
9.2 Saudi Arabia Drug Reprofiling Revenue and Growth Rate (2015-2020)
9.3 UAE Drug Reprofiling Revenue and Growth Rate (2015-2020)
9.4 Egypt Drug Reprofiling Revenue and Growth Rate (2015-2020)
9.5 South Africa Drug Reprofiling Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Drug Reprofiling Revenue and Market Share by Type (2015-2020)
10.2 Global Drug Reprofiling Market Forecast by Type (2019-2024)
10.3 Orally Revenue Growth Rate (2015-2025)
10.4 Intravenously Revenue Growth Rate (2015-2025)
11 Global Drug Reprofiling Market Segment by Application
11.1 Global Drug Reprofiling Revenue Market Share by Application (2015-2020)
11.2 Drug Reprofiling Market Forecast by Application (2019-2024)
11.3 Central Nervous Disorders Revenue Growth (2015-2020)
11.4 Cardiovascular Disorders Revenue Growth (2015-2020)
11.5 Oncology Revenue Growth (2015-2020)
11.6 others Revenue Growth (2015-2020)
12 Global Drug Reprofiling Market Size Forecast (2021-2025)
12.1 Global Drug Reprofiling Market Size Forecast (2021-2025)
12.2 Global Drug Reprofiling Market Forecast by Regions (2021-2025)
12.3 North America Drug Reprofiling Revenue Market Forecast (2021-2025)
12.4 Europe Drug Reprofiling Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Drug Reprofiling Revenue Market Forecast (2021-2025)
12.6 South America Drug Reprofiling Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Drug Reprofiling Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Drug Reprofiling Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Drug Reprofiling by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Drug Reprofiling Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Drug Reprofiling Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Drug Reprofiling Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Novartis AG Corporate Information, Location and Competitors
Table 7. Novartis AG Drug Reprofiling Major Business
Table 8. Novartis AG Drug Reprofiling Total Revenue (USD Million) (2017-2018)
Table 9. Novartis AG SWOT Analysis
Table 10. Novartis AG Drug Reprofiling Product and Solutions
Table 11. Novartis AG Drug Reprofiling Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Teva Pharmaceuticals Corporate Information, Location and Competitors
Table 13. Teva Pharmaceuticals Drug Reprofiling Major Business
Table 14. Teva Pharmaceuticals Drug Reprofiling Total Revenue (USD Million) (2018-2019)
Table 15. Teva Pharmaceuticals SWOT Analysis
Table 16. Teva Pharmaceuticals Drug Reprofiling Product and Solutions
Table 17. Teva Pharmaceuticals Drug Reprofiling Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Johnson & Johnson Corporate Information, Location and Competitors
Table 19. Johnson & Johnson Drug Reprofiling Major Business
Table 20. Johnson & Johnson Drug Reprofiling Total Revenue (USD Million) (2017-2018)
Table 21. Johnson & Johnson SWOT Analysis
Table 22. Johnson & Johnson Drug Reprofiling Product and Solutions
Table 23. Johnson & Johnson Drug Reprofiling Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Abbott Healthcare Corporate Information, Location and Competitors
Table 25. Abbott Healthcare Drug Reprofiling Major Business
Table 26. Abbott Healthcare Drug Reprofiling Total Revenue (USD Million) (2017-2018)
Table 27. Abbott Healthcare SWOT Analysis
Table 28. Abbott Healthcare Drug Reprofiling Product and Solutions
Table 29. Abbott Healthcare Drug Reprofiling Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Mylan Inc. Corporate Information, Location and Competitors
Table 31. Mylan Inc. Drug Reprofiling Major Business
Table 32. Mylan Inc. Drug Reprofiling Total Revenue (USD Million) (2017-2018)
Table 33. Mylan Inc. SWOT Analysis
Table 34. Mylan Inc. Drug Reprofiling Product and Solutions
Table 35. Mylan Inc. Drug Reprofiling Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Pfizer Corporate Information, Location and Competitors
Table 37. Pfizer Drug Reprofiling Major Business
Table 38. Pfizer Drug Reprofiling Total Revenue (USD Million) (2017-2018)
Table 39. Pfizer SWOT Analysis
Table 40. Pfizer Drug Reprofiling Product and Solutions
Table 41. Pfizer Drug Reprofiling Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Sandoz Corporate Information, Location and Competitors
Table 43. Sandoz Drug Reprofiling Major Business
Table 44. Sandoz Drug Reprofiling Total Revenue (USD Million) (2017-2018)
Table 45. Sandoz SWOT Analysis
Table 46. Sandoz Drug Reprofiling Product and Solutions
Table 47. Sandoz Drug Reprofiling Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Hoffmann-La Roche Corporate Information, Location and Competitors
Table 49. Hoffmann-La Roche Drug Reprofiling Major Business
Table 50. Hoffmann-La Roche Drug Reprofiling Total Revenue (USD Million) (2017-2018)
Table 51. Hoffmann-La Roche SWOT Analysis
Table 52. Hoffmann-La Roche Drug Reprofiling Product and Solutions
Table 53. Hoffmann-La Roche Drug Reprofiling Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Global Drug Reprofiling Revenue (Million USD) by Players (2015-2020)
Table 55. Global Drug Reprofiling Revenue Share by Players (2015-2020)
Table 56. Global Drug Reprofiling Revenue (Million USD) by Regions (2015-2020)
Table 57. Global Drug Reprofiling Revenue Market Share by Regions (2015-2020)
Table 58. North America Drug Reprofiling Revenue by Countries (2015-2020)
Table 59. North America Drug Reprofiling Revenue Market Share by Countries (2015-2020)
Table 60. Europe Drug Reprofiling Revenue (Million USD) by Countries (2015-2020)
Table 61. Asia-Pacific Drug Reprofiling Revenue (Million USD) by Countries (2015-2020)
Table 62. South America Drug Reprofiling Revenue by Countries (2015-2020)
Table 63. South America Drug Reprofiling Revenue Market Share by Countries (2015-2020)
Table 64. Middle East and Africa Drug Reprofiling Revenue (Million USD) by Countries (2015-2020)
Table 65. Middle East and Africa Drug Reprofiling Revenue Market Share by Countries (2015-2020)
Table 66. Global Drug Reprofiling Revenue (Million USD) by Type (2015-2020)
Table 67. Global Drug Reprofiling Revenue Share by Type (2015-2020)
Table 68. Global Drug Reprofiling Revenue Forecast by Type (2021-2025)
Table 69. Global Drug Reprofiling Revenue by Application (2015-2020)
Table 70. Global Drug Reprofiling Revenue Share by Application (2015-2020)
Table 71. Global Drug Reprofiling Revenue Forecast by Application (2021-2025)
Table 72. Global Drug Reprofiling Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Drug Reprofiling Picture
Figure 2. Global Drug Reprofiling Revenue Market Share by Type in 2019
Figure 3. Orally Picture
Figure 4. Intravenously Picture
Figure 5. Drug Reprofiling Revenue Market Share by Application in 2019
Figure 6. Central Nervous Disorders Picture
Figure 7. Cardiovascular Disorders Picture
Figure 8. Oncology Picture
Figure 9. others Picture
Figure 10. Global Drug Reprofiling Revenue (USD Million) and Growth Rate (2015-2025)
Figure 11. North America Drug Reprofiling Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Europe Drug Reprofiling Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Asia-Pacific Drug Reprofiling Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. South America Drug Reprofiling Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Middle East and Africa Drug Reprofiling Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Drug Reprofiling Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Drug Reprofiling Revenue Share by Players in 2019
Figure 18. Global Top 5 Players Drug Reprofiling Revenue Market Share in 2019
Figure 19. Global Top 10 Players Drug Reprofiling Revenue Market Share in 2019
Figure 20. Key Players Market Share Trend
Figure 21. Global Drug Reprofiling Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 22. Global Drug Reprofiling Revenue Market Share by Regions (2015-2020)
Figure 23. Global Drug Reprofiling Revenue Market Share by Regions in 2018
Figure 24. North America Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 25. Europe Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 26. Asia-Pacific Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 27. South America Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 28. Middle East and Africa Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 29. North America Drug Reprofiling Revenue Market Share by Countries (2015-2020)
Figure 30. North America Drug Reprofiling Revenue Market Share by Countries in 2019
Figure 31. USA Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 32. Canada Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 33. Mexico Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 34. Europe Drug Reprofiling Revenue Market Share by Countries (2015-2020)
Figure 35. Europe Drug Reprofiling Revenue Market Share by Countries in 2019
Figure 36. Germany Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 37. UK Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 38. France Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 39. Russia Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 40. Italy Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Drug Reprofiling Revenue Market Share by Countries (2015-2020)
Figure 42. Asia-Pacific Drug Reprofiling Revenue Market Share by Countries in 2019
Figure 43. China Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 44. Japan Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 45. Korea Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 46. India Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 47. Southeast Asia Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 48. South America Drug Reprofiling Revenue Market Share by Countries (2015-2020)
Figure 49. South America Drug Reprofiling Revenue Market Share by Countries in 2019
Figure 50. Brazil Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 51. Argentina Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 52. Middle East and Africa Drug Reprofiling Revenue Market Share by Countries (2015-2020)
Figure 53. Middle East and Africa Drug Reprofiling Revenue Market Share by Countries in 2019
Figure 54. Saudi Arabia Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 55. UAE Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 56. Egypt Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 57. South Africa Drug Reprofiling Revenue and Growth Rate (2015-2020)
Figure 58. Global Drug Reprofiling Revenue Share by Type (2015-2020)
Figure 59. Global Drug Reprofiling Revenue Share by Type in 2019
Figure 60. Global Drug Reprofiling Market Share Forecast by Type (2021-2025)
Figure 61. Global Orally Revenue Growth Rate (2015-2020)
Figure 62. Global Intravenously Revenue Growth Rate (2015-2020)
Figure 63. Global Drug Reprofiling Revenue Share by Application (2015-2020)
Figure 64. Global Drug Reprofiling Revenue Share by Application in 2019
Figure 65. Global Drug Reprofiling Market Share Forecast by Application (2021-2025)
Figure 66. Global Central Nervous Disorders Revenue Growth Rate (2015-2020)
Figure 67. Global Cardiovascular Disorders Revenue Growth Rate (2015-2020)
Figure 68. Global Oncology Revenue Growth Rate (2015-2020)
Figure 69. Global others Revenue Growth Rate (2015-2020)
Figure 70. Global Drug Reprofiling Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 71. Global Drug Reprofiling Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 72. Global Drug Reprofiling Revenue Market Share Forecast by Regions (2021-2025)
Figure 73. North America Drug Reprofiling Revenue Market Forecast (2021-2025)
Figure 74. Europe Drug Reprofiling Revenue Market Forecast (2021-2025)
Figure 75. Asia-Pacific Drug Reprofiling Revenue Market Forecast (2021-2025)
Figure 76. South America Drug Reprofiling Revenue Market Forecast (2021-2025)
Figure 77. Middle East and Africa Drug Reprofiling Revenue Market Forecast (2021-2025)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
鎮痛剤デリバリーの世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Pain Drug Delivery market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Pain Drug Delivery market …- 急性肝性ポルフィリン症治療薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Acute Hepatic Porphyria Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimi…
- 抗コリン薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Anticholinergic Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, …
- ノイラミニダーゼ阻害薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Neuraminidase Inhibitors Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optim…
- エリスロポエチン治療薬の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Erythropoietin Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 5.5% in the forecast period of 2020 to 2025 and will expected to reach USD 10830 million by 2025, from USD 8727.6 million in 2019. The Erythropoietin Dr…